FR18C1049I2 - Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one - Google Patents

Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one

Info

Publication number: FR18C1049I2
Authority: FR; France
Prior art keywords: azepino; polymorphs; indol; methylamino; tetrahydro
Prior art date: 2010-02-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

FR18C1049C

Other languages

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Corp Belgium

Pfizer Corp SRL

Original Assignee

Pfizer Corp Belgium

Pfizer Corp SRL

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-02-12

Filing date

2018-11-21

Publication date

2021-01-08

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43859823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR18C1049(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-11-21 Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium

2019-02-15 Publication of FR18C1049I1 publication Critical patent/FR18C1049I1/fr

2021-01-08 Application granted granted Critical

2021-01-08 Publication of FR18C1049I2 publication Critical patent/FR18C1049I2/fr

Status Active legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/19—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Reproductive Health (AREA)
Dermatology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

FR18C1049C 2010-02-12 2018-11-21 Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one Active FR18C1049I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US30427710P	2010-02-12	2010-02-12
PCT/IB2011/050571 WO2011098971A1 (fr)	2010-02-12	2011-02-10	Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one

Publications (2)

Publication Number	Publication Date
FR18C1049I1 FR18C1049I1 (fr)	2019-02-15
FR18C1049I2 true FR18C1049I2 (fr)	2021-01-08

Family

ID=43859823

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR18C1049C Active FR18C1049I2 (fr)	2010-02-12	2018-11-21	Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one

Country Status (32)

Country	Link
US (5)	US8754072B2 (fr)
EP (4)	EP3150610B1 (fr)
JP (6)	JP5745283B2 (fr)
KR (2)	KR20120127495A (fr)
CN (2)	CN102884066B (fr)
AR (2)	AR080164A1 (fr)
AU (1)	AU2011213944B2 (fr)
BR (1)	BR112012019050B1 (fr)
CA (2)	CA3024216C (fr)
CY (3)	CY1118319T1 (fr)
DK (2)	DK2534153T4 (fr)
ES (2)	ES2753748T3 (fr)
FI (1)	FI2534153T4 (fr)
FR (1)	FR18C1049I2 (fr)
HR (2)	HRP20161742T4 (fr)
HU (3)	HUE030969T4 (fr)
IL (1)	IL220921B (fr)
LT (3)	LT3150610T (fr)
LU (1)	LUC00093I2 (fr)
MX (1)	MX343383B (fr)
NL (1)	NL300958I2 (fr)
NO (1)	NO2018039I1 (fr)
NZ (1)	NZ601445A (fr)
PL (2)	PL3150610T3 (fr)
PT (2)	PT3150610T (fr)
RS (2)	RS55487B2 (fr)
RU (1)	RU2570198C2 (fr)
SG (2)	SG10201406805RA (fr)
SI (2)	SI2534153T2 (fr)
SM (3)	SMT201900634T1 (fr)
TW (1)	TWI545123B (fr)
WO (1)	WO2011098971A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3024216C (fr) *	2010-02-12	2021-03-30	Pfizer Inc.	Sels et polymorphes de la 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
TW201516636A (zh) *	2013-10-22	2015-05-01	Hon Hai Prec Ind Co Ltd	電子裝置及其供電方法
RS67356B1 (sr) *	2014-08-22	2025-11-28	Pharma& Schweiz Gmbh	Tablete rukapariba visoke doze
WO2017199903A1 (fr)	2016-05-16	2017-11-23	帝人ファーマ株式会社	Cristal de dérivé de quinoléine
DE102016218772A1 (de) *	2016-09-28	2018-03-29	Bruker Biospin Gmbh	Verbesserte Temperierung eines NMR-MAS-Rotors
US10875870B2 (en)	2017-01-24	2020-12-29	Assia Chemical Industries Ltd.	Solid state forms of rucaparib and of rucaparib salts
CN109651377B (zh) *	2017-10-12	2020-10-20	成都海创药业有限公司	一种治疗癌症的化合物及其用途
MX2020004545A (es) *	2017-11-03	2020-08-03	Sandoz Ag	Sal cristralina de un inhibidor triciclico de poli(adp-ribosa)-polimerasa.
WO2019115000A1 (fr) *	2017-12-15	2019-06-20	Advitech Advisory And Technologies Sa	Procédé de préparation de rucaparib et nouveaux intermédiaires de synthèse
WO2019130229A1 (fr)	2017-12-28	2019-07-04	Mylan Laboratories Ltd	Procédés et intermédiaires pouvant être utilisés pour la préparation de rucaparib
US10933069B2 (en)	2018-01-05	2021-03-02	Cybrexa 1, Inc.	Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US10442813B2 (en)	2018-01-30	2019-10-15	RK Pharma Solutions LLC	Polymorphs of rucaparib camsylate and methods of making same
WO2019207498A1 (fr) *	2018-04-25	2019-10-31	Biophore India Pharmaceuticals Pvt. Ltd	Formes solides de sel d'acide 8-fluoro-2-{4-[(méthylamino)méthyl] phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd] indol-6-one ((1s,4r)-7,7diméthyl-2-oxobicyclo [2.2.1] hept-1-yl) méthanesulfonique (rucaparib camsylate) et la préparation de ceux-ci
WO2019207596A1 (fr)	2018-04-25	2019-10-31	Mylan Laboratories Limited	Nouvelles formes cristallines du sel de rucaparib (s)-camsylate et base exempte de rucaparib
CN108743557A (zh) *	2018-06-27	2018-11-06	李莉	一种磷酸瑞卡帕布软胶囊及其制备方法
CN109111454A (zh) *	2018-08-01	2019-01-01	宁波金未生物科技有限公司	一种瑞卡帕布s-樟脑磺酸盐
WO2020087170A1 (fr)	2018-10-30	2020-05-07	Repare Therapeutics Inc.	Composés, compositions pharmaceutiques, procédés de préparation de composés et leur utilisation en tant qu'inhibiteurs de kinase atr
CN111217818A (zh) *	2018-11-27	2020-06-02	台耀化学股份有限公司	芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
WO2020113500A1 (fr) *	2018-12-06	2020-06-11	上海诚妙医药科技有限公司	Rucarapib camsylate, son procédé de préparation et ses applications
EP3997093A1 (fr)	2019-07-10	2022-05-18	Cybrexa 2, Inc.	Conjugués peptidiques de cytotoxines servant d'agents thérapeutiques
PH12022550037A1 (en)	2019-07-10	2023-04-12	Cybrexa 3 Inc	Peptide conjugates of microtubule-targeting agents as therapeutics
CN111004244A (zh) *	2019-12-27	2020-04-14	重庆市碚圣医药科技股份有限公司	一种瑞卡帕布樟脑磺酸盐的合成方法
EP4100125A1 (fr)	2020-02-03	2022-12-14	Sandoz AG	Polymorphe de mésylate de rucaparib
PE20221838A1 (es) *	2020-04-24	2022-11-29	Astrazeneca Ab	Formulaciones farmaceuticas
ES3014370T3 (en)	2020-04-28	2025-04-22	Rhizen Pharmaceuticals Ag	Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4178571A4 (fr)	2020-07-10	2024-07-17	The Regents Of The University Of Michigan	Inhibiteurs de gas41 et leurs méthodes d'utilisation
EP4182318B1 (fr)	2020-07-14	2025-08-27	Assia Chemical Industries Ltd.	Formes à l'état solide de sels de rucaparib
WO2022090938A1 (fr)	2020-10-31	2022-05-05	Rhizen Pharmaceuticals Ag	Dérivés de phtalazinone utiles en tant qu'inhibiteurs de parp
AU2022255809A1 (en)	2021-04-08	2023-10-26	Incozen Therapeutics Pvt. Ltd.	Inhibitors of poly(adp-ribose) polymerase
EP4463232A1 (fr)	2022-01-11	2024-11-20	Assia Chemical Industries Ltd.	Formes à l'état solide de tosylate de rucaparib
WO2023152754A1 (fr) *	2022-02-08	2023-08-17	Sawant, Mohit Manikrao	Forme cristalline d'ester allylique de rosuvastatine
AU2022489881A1 (en) *	2022-11-30	2025-06-19	Ideaya Biosciences, Inc.	2-oxoquinazoline crystalline forms

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4489011A (en)	1983-05-16	1984-12-18	Merrell Dow Pharmaceuticals Inc.	Hypoglycemic N-(2-substituted-3-dialkylamino-2-propenylidene)-N-alkylalkanaminium camsylate salts
GB8607683D0 (en)	1986-03-27	1986-04-30	Ici Plc	Anti-tumor agents
GB8608335D0 (en)	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
DE4125292A1 (de) *	1991-07-31	1993-02-04	Kali Chemie Pharma Gmbh	6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
ATE419355T1 (de)	1992-02-06	2009-01-15	Novartis Vaccines & Diagnostic	Marker für krebs und biosynthetisches bindeprotein dafür
US6177401B1 (en)	1992-11-13	2001-01-23	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften	Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
CA2218503C (fr)	1995-04-20	2001-07-24	Pfizer Inc.	Derives d'acide hydroxamique arylsufonyle en tant qu'inhibiteurs de mmp et de tnf
US5747498A (en)	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en)	1995-06-07	1999-03-09	Sugen, Inc.	Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en)	1995-10-11	1995-12-13	Wellcome Found	Therapeutically active compounds
GB9624482D0 (en)	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
EP0780386B1 (fr)	1995-12-20	2002-10-02	F. Hoffmann-La Roche Ag	Inhibiteurs de métalloprotéases matricielles
PT885198E (pt)	1996-03-05	2002-06-28	Astrazeneca Ab	Derivados de 4-anilinoquinazolina
JP3195756B2 (ja)	1996-07-04	2001-08-06	公子吉水	潤滑補助体
EP0818442A3 (fr)	1996-07-12	1998-12-30	Pfizer Inc.	Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
DE69718472T2 (de)	1996-07-13	2003-11-06	Glaxo Group Ltd., Greenford	Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
EP0912559B1 (fr)	1996-07-13	2002-11-06	Glaxo Group Limited	Composes heterocycliques condenses en tant qu'inhibiteurs de la proteine tyrosine kinase
HRP970371A2 (en)	1996-07-13	1998-08-31	Kathryn Jane Smith	Heterocyclic compounds
KR20000067904A (ko)	1996-07-18	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	매트릭스 메탈로프로테아제의 포스피네이트계 억제제
BR9711223A (pt)	1996-08-23	1999-08-17	Pfizer	Derivados de cido arilsulfonilamino-hidrox mico
ID18494A (id)	1996-10-02	1998-04-16	Novartis Ag	Turunan pirazola leburan dan proses pembuatannya
EP0950059B1 (fr)	1997-01-06	2004-08-04	Pfizer Inc.	Derives de sulfone cyclique
IL131042A0 (en)	1997-02-03	2001-01-28	Pfizer Prod Inc	Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (pt)	1997-02-07	2000-03-08	Pfizer	Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
KR20000070923A (ko)	1997-02-11	2000-11-25	디. 제이. 우드, 스피겔 알렌 제이	아릴설포닐 하이드록삼산 유도체
WO1998050356A1 (fr)	1997-05-07	1998-11-12	Sugen, Inc.	Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
AU734009B2 (en)	1997-05-30	2001-05-31	Merck & Co., Inc.	Novel angiogenesis inhibitors
US5835420A (en)	1997-06-27	1998-11-10	Aplus Flash Technology, Inc.	Node-precise voltage regulation for a MOS memory system
DE69822839T2 (de)	1997-08-08	2004-08-19	Pfizer Products Inc., Groton	Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
AU8816298A (en)	1997-08-22	1999-03-16	Zeneca Limited	Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (fr)	1997-09-26	2000-11-08	Merck & Co Inc	Nouveaux inhibiteurs de l'angiogenese
HUP0100287A3 (en)	1997-11-11	2003-04-28	Pfizer Prod Inc	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
GB9800575D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9800569D0 (en)	1998-01-12	1998-03-11	Glaxo Group Ltd	Heterocyclic compounds
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
JP4462654B2 (ja)	1998-03-26	2010-05-12	ソニー株式会社	映像素材選択装置及び映像素材選択方法
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
CA2314156C (fr)	1998-05-29	2010-05-25	Sugen, Inc.	Inhibiteurs de la proteine kinase 2-indolinone a substitution pyrrole
UA60365C2 (uk)	1998-06-04	2003-10-15	Пфайзер Продактс Інк.	Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
ES2213985T3 (es)	1998-11-05	2004-09-01	Pfizer Products Inc.	Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
JP2002533404A (ja)	1998-12-23	2002-10-08	ジー・ディー・サール・アンド・カンパニー	新生物形成の治療における組合わせ療法としてインテグリン拮抗剤及び放射線治療を使用する方法
US6649645B1 (en)	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
PL210415B1 (pl)	1999-01-11	2012-01-31	Agouron Pharma	Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
KR100452491B1 (ko)	2001-03-29	2004-10-12	한미약품 주식회사	신규한 결정형 암로디핀 캠실레이트 염 및 그의 제조방법
KR20040011751A (ko)	2002-07-30	2004-02-11	씨제이 주식회사	암로디핀의 유기산염
EP1575936A1 (fr) †	2002-12-19	2005-09-21	Pfizer Products Inc.	Complexes de e-2-methoxy-n-(3- 4- 3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl -allyl)-acetamide et procédés de fabrication et d'utilisation correspondants
EP1611137A1 (fr)	2003-03-31	2006-01-04	Pfizer Inc.	Sels d'inhibiteurs tricycliques de poly(adp-ribose) polymerases
ATE454893T1 (de)	2003-07-25	2010-01-15	Cancer Rec Tech Ltd	Tricyclische parp-hemmer
MX2007003311A (es) *	2004-09-22	2007-05-16	Pfizer	Procedimiento para preparar inhibidores de poli (adp-ribosa) polimerasas.
JP2008513435A (ja) *	2004-09-22	2008-05-01	ファイザー・インク	ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
CN101384264B (zh) *	2004-09-22	2012-03-14	辉瑞大药厂	含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
MX2007002461A (es)	2004-09-22	2008-03-13	Pfizer	Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
GB0502509D0 (en)	2005-02-07	2005-03-16	Pfizer Ltd	Novel salt form of a dopamine agonist
KR20140103356A (ko) *	2005-02-23	2014-08-26	테바 파마슈티컬 인더스트리즈 리미티드	함량 균일성이 개선된 라사길린 제형
EP1886670A1 (fr) *	2006-07-05	2008-02-13	Teva Pharmaceutical Industries Ltd	Compositions pharmaceutiques de memantine
KR100843401B1 (ko)	2006-12-04	2008-07-04	씨제이제일제당 (주)	결정성 ｓ-(-)-암로디핀 캠실레이트 무수물 및 이의제조방법
PT2091910E (pt) *	2006-12-06	2014-11-18	Conatus Pharmaceuticals Inc	Formas cristalinas do ácido (3s)-3-[n-(n¿-(2-tercbutilfenil) oxamil)alaninil]amino-5-(2¿,3¿,5¿,6¿- tetrafluorofenoxi)-4-oxopentanóico
WO2008114114A2 (fr)	2007-03-16	2008-09-25	Pfizer Products Inc.	Inhibiteurs de poly(adp-ribose)polymérases pour le traitement d'une condition ophtalmique
EP2065385A1 (fr) †	2007-11-28	2009-06-03	Laboratorios SALVAT, S.A.	Sel cristallin stable de (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabiciyclo [2.2.2]oct-3-yl ester
US20110053997A1 (en) *	2007-12-05	2011-03-03	Alexander Beliaev	Salts and Crystal Forms
KR20090060674A (ko)	2007-12-10	2009-06-15	씨제이제일제당 (주)	결정형의 지프라시돈 술폰산염, 그 제조방법, 및 그것를포함하는 약제학적 조성물
NZ586675A (en)	2008-01-08	2012-04-27	Merck Sharp & Dohme	Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
BRPI1006813A2 (pt)	2009-01-17	2016-04-12	Boomerang Systems Inc	sistema de armazenamento automático e veículo de transporte
CA3024216C (fr) *	2010-02-12	2021-03-30	Pfizer Inc.	Sels et polymorphes de la 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US9539930B2 (en)	2011-09-23	2017-01-10	Gentex Corporation	Systems and methods for rear view mirror displays
MX2014007691A (es)	2011-12-26	2015-02-10	Wintech Polymer Ltd	Gránulos de resina de polibutilentereftalato, y método de producción para dichos gránulos de resina de polibutilenterftalato .
US9384339B2 (en)	2012-01-13	2016-07-05	Telecommunication Systems, Inc.	Authenticating cloud computing enabling secure services
US9672526B2 (en)	2012-03-13	2017-06-06	American Express Travel Related Services Company, Inc.	Systems and methods for tailoring marketing
KR101984831B1 (ko)	2013-01-31	2019-05-31	삼성전자 주식회사	반도체 패키지 및 그 제조 방법
CN103309115B (zh)	2013-05-30	2016-03-23	京东方科技集团股份有限公司	彩色电泳显示面板及其制造方法、显示装置
US9501163B2 (en)	2014-05-06	2016-11-22	Symbol Technologies, Llc	Apparatus and method for activating a trigger mechanism
US10884952B2 (en)	2016-09-30	2021-01-05	Intel Corporation	Enforcing memory operand types using protection keys
JP6943759B2 (ja)	2017-12-28	2021-10-06	株式会社東海理化電機製作所	シフト装置

2011
- 2011-02-10 CA CA3024216A patent/CA3024216C/fr active Active
- 2011-02-10 LT LT16183844T patent/LT3150610T/lt unknown
- 2011-02-10 SM SM20190634T patent/SMT201900634T1/it unknown
- 2011-02-10 PT PT161838446T patent/PT3150610T/pt unknown
- 2011-02-10 KR KR1020127023813A patent/KR20120127495A/ko not_active Ceased
- 2011-02-10 NZ NZ601445A patent/NZ601445A/en unknown
- 2011-02-10 HR HRP20161742TT patent/HRP20161742T4/hr unknown
- 2011-02-10 PL PL16183844T patent/PL3150610T3/pl unknown
- 2011-02-10 MX MX2012008911A patent/MX343383B/es active IP Right Grant
- 2011-02-10 RU RU2012138892/04A patent/RU2570198C2/ru active
- 2011-02-10 AU AU2011213944A patent/AU2011213944B2/en active Active
- 2011-02-10 JP JP2011026718A patent/JP5745283B2/ja active Active
- 2011-02-10 EP EP16183844.6A patent/EP3150610B1/fr active Active
- 2011-02-10 SI SI201131051T patent/SI2534153T2/sl unknown
- 2011-02-10 DK DK11708094.5T patent/DK2534153T4/da active
- 2011-02-10 ES ES16183844T patent/ES2753748T3/es active Active
- 2011-02-10 PT PT117080945T patent/PT2534153T/pt unknown
- 2011-02-10 CN CN201180009237.0A patent/CN102884066B/zh active Active
- 2011-02-10 LT LTEP11708094.5T patent/LT2534153T/lt unknown
- 2011-02-10 EP EP22199074.0A patent/EP4166558A1/fr active Pending
- 2011-02-10 RS RS20161117A patent/RS55487B2/sr unknown
- 2011-02-10 ES ES11708094T patent/ES2607806T5/es active Active
- 2011-02-10 DK DK16183844T patent/DK3150610T3/da active
- 2011-02-10 SM SM20160462T patent/SMT201600462T1/it unknown
- 2011-02-10 WO PCT/IB2011/050571 patent/WO2011098971A1/fr not_active Ceased
- 2011-02-10 KR KR1020197005968A patent/KR102108226B1/ko active Active
- 2011-02-10 RS RS20191394A patent/RS59494B1/sr unknown
- 2011-02-10 CA CA2787881A patent/CA2787881C/fr active Active
- 2011-02-10 HU HUE11708094A patent/HUE030969T4/hu unknown
- 2011-02-10 US US13/522,549 patent/US8754072B2/en active Active
- 2011-02-10 HU HUE16183844A patent/HUE047248T2/hu unknown
- 2011-02-10 BR BR112012019050-4A patent/BR112012019050B1/pt not_active IP Right Cessation
- 2011-02-10 PL PL11708094.5T patent/PL2534153T5/pl unknown
- 2011-02-10 SG SG10201406805RA patent/SG10201406805RA/en unknown
- 2011-02-10 SG SG2012052171A patent/SG182533A1/en unknown
- 2011-02-10 SI SI201131808T patent/SI3150610T1/sl unknown
- 2011-02-10 CN CN201410818193.1A patent/CN104876937B/zh active Active
- 2011-02-10 EP EP19178840.5A patent/EP3597651A1/fr not_active Withdrawn
- 2011-02-10 EP EP11708094.5A patent/EP2534153B2/fr active Active
- 2011-02-11 AR ARP110100427A patent/AR080164A1/es not_active Application Discontinuation
- 2011-02-11 TW TW100104676A patent/TWI545123B/zh active
2012
- 2012-07-12 IL IL220921A patent/IL220921B/en active IP Right Grant
2014
- 2014-05-08 US US14/272,589 patent/US9045487B2/en active Active
2015
- 2015-04-21 JP JP2015086722A patent/JP6013551B2/ja active Active
- 2015-04-28 US US14/698,463 patent/US9861638B2/en active Active
2016
- 2016-09-21 JP JP2016183846A patent/JP6371350B2/ja active Active
- 2016-12-13 CY CY20161101288T patent/CY1118319T1/el unknown
- 2016-12-21 SM SM201600462T patent/SMT201600462B/it unknown
2017
- 2017-08-16 AR ARP170102290A patent/AR109356A2/es unknown
- 2017-12-06 US US15/833,073 patent/US10278974B2/en active Active
2018
- 2018-07-12 JP JP2018132270A patent/JP6640931B2/ja active Active
- 2018-11-13 CY CY2018031C patent/CY2018031I2/el unknown
- 2018-11-13 LU LU00093C patent/LUC00093I2/fr unknown
- 2018-11-14 HU HUS1800046C patent/HUS1800046I1/hu unknown
- 2018-11-15 LT LTPA2018517C patent/LTC2534153I2/lt unknown
- 2018-11-15 NO NO2018039C patent/NO2018039I1/no unknown
- 2018-11-16 FI FIEP11708094.5T patent/FI2534153T4/fi active
- 2018-11-19 NL NL300958C patent/NL300958I2/nl unknown
- 2018-11-21 FR FR18C1049C patent/FR18C1049I2/fr active Active
2019
- 2019-02-28 US US16/288,615 patent/US20200000821A1/en not_active Abandoned
- 2019-10-25 HR HRP20191944TT patent/HRP20191944T1/hr unknown
- 2019-10-31 CY CY20191101132T patent/CY1122218T1/el unknown
- 2019-12-26 JP JP2019235421A patent/JP2020050671A/ja not_active Withdrawn
2021
- 2021-05-06 JP JP2021078485A patent/JP2021107460A/ja active Pending

Also Published As

Publication number	Publication date
ES2607806T3 (es)	2017-04-04
JP2011168587A (ja)	2011-09-01
MX343383B (es)	2016-11-03
EP3150610A1 (fr)	2017-04-05
NZ601445A (en)	2014-08-29
US20140243318A1 (en)	2014-08-28
PT3150610T (pt)	2019-11-11
TW201144316A (en)	2011-12-16
AR109356A2 (es)	2018-11-21
CN102884066A (zh)	2013-01-16
EP3150610B1 (fr)	2019-07-31
EP2534153A1 (fr)	2012-12-19
JP2020050671A (ja)	2020-04-02
JP6640931B2 (ja)	2020-02-05
BR112012019050A2 (pt)	2016-09-13
HRP20191944T1 (hr)	2020-01-24
IL220921B (en)	2020-03-31
LUC00093I2 (fr)	2019-12-24
DK2534153T4 (da)	2024-06-03
TWI545123B (zh)	2016-08-11
CA2787881A1 (fr)	2011-08-18
JP5745283B2 (ja)	2015-07-08
KR20190026043A (ko)	2019-03-12
LTPA2018517I1 (lt)	2018-12-10
FR18C1049I1 (fr)	2019-02-15
US8754072B2 (en)	2014-06-17
SG182533A1 (en)	2012-08-30
US20150238504A1 (en)	2015-08-27
MX2012008911A (es)	2012-08-15
CN104876937A (zh)	2015-09-02
BR112012019050A8 (pt)	2017-12-26
AR080164A1 (es)	2012-03-21
RS55487B2 (sr)	2024-06-28
CY1122218T1 (el)	2020-11-25
SG10201406805RA (en)	2014-11-27
AU2011213944A1 (en)	2012-08-09
AU2011213944B2 (en)	2014-10-02
HRP20161742T4 (hr)	2024-07-05
JP6371350B2 (ja)	2018-08-08
FI2534153T4 (fi)	2024-06-26
PL3150610T3 (pl)	2020-02-28
NO2018039I1 (no)	2018-11-15
DK3150610T3 (da)	2019-11-04
SI3150610T1 (sl)	2019-12-31
HRP20161742T1 (hr)	2017-02-24
LUC00093I1 (fr)	2018-11-15
RU2012138892A (ru)	2014-03-20
ES2607806T5 (es)	2024-10-07
EP2534153B1 (fr)	2016-09-21
HUS1800046I1 (hu)	2018-12-28
JP2016216507A (ja)	2016-12-22
CA2787881C (fr)	2019-01-08
LT2534153T (lt)	2016-12-12
NL300958I2 (nl)	2018-12-19
US20120302550A1 (en)	2012-11-29
US20180092925A1 (en)	2018-04-05
CY1118319T1 (el)	2017-06-28
HUE030969T2 (en)	2017-06-28
CA3024216A1 (fr)	2011-08-18
US20200000821A1 (en)	2020-01-02
PL2534153T3 (pl)	2017-08-31
SMT201600462B (it)	2017-03-08
KR102108226B1 (ko)	2020-05-08
DK2534153T3 (en)	2017-01-09
HUE030969T4 (hu)	2024-11-28
SMT201600462T1 (it)	2017-03-08
SI2534153T2 (sl)	2024-07-31
CN102884066B (zh)	2015-01-07
JP2021107460A (ja)	2021-07-29
JP6013551B2 (ja)	2016-10-25
ES2753748T3 (es)	2020-04-14
BR112012019050B1 (pt)	2021-12-21
CY2018031I1 (el)	2019-11-27
KR20120127495A (ko)	2012-11-21
US9861638B2 (en)	2018-01-09
US10278974B2 (en)	2019-05-07
RS55487B1 (sr)	2017-04-28
HUE047248T2 (hu)	2020-04-28
PT2534153T (pt)	2016-12-27
EP2534153B2 (fr)	2024-05-22
WO2011098971A1 (fr)	2011-08-18
EP3597651A1 (fr)	2020-01-22
HK1176617A1 (zh)	2013-08-02
LTC2534153I2 (lt)	2021-03-10
CA3024216C (fr)	2021-03-30
SI2534153T1 (sl)	2017-01-31
EP4166558A1 (fr)	2023-04-19
US9045487B2 (en)	2015-06-02
LT3150610T (lt)	2019-11-11
JP2018199679A (ja)	2018-12-20
RS59494B1 (sr)	2019-12-31
SMT201900634T1 (it)	2020-01-14
JP2015131858A (ja)	2015-07-23
CY2018031I2 (el)	2019-11-27
PL2534153T5 (pl)	2024-11-18
CN104876937B (zh)	2017-07-28
RU2570198C2 (ru)	2015-12-10

Publication	Publication Date	Title
FR18C1049I2 (fr)	2021-01-08	Sels et polymorphes de la 8-fluoro-2-{4-[(méthylamino}méthyl]phényl}-1,3,4,5-tétrahydro-6h-azépino[5,4,3-cd]indol-6-one
NO2022018I1 (no)	2022-05-31	Avacopan samt farmaceutisk acceptable salte deraf
DK2341784T3 (da)	2013-02-04	Næringspræparater med coatede lipidkugler
NO2019010I1 (no)	2019-03-01	Eravasyklin eller farmasøytisk akseptable salter derav
PL2504336T3 (pl)	2016-10-31	Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
PL3095452T3 (pl)	2020-05-18	Stosowanie kannabidiolu w połączeniu z arypiprazolem
IL244231A0 (en)	2016-04-21	Methods for producing aripiprazole suspension and freeze-dried formulation
BRPI1011066A2 (pt)	2017-03-21	"pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
BRPI0913710A2 (pt)	2015-10-13	"artigo e métodos para preparação do artigo"
BRPI0710944A2 (pt)	2017-04-18	uso de bactéria selecionada de ácido lático para reduzir cólicas infantis
DK2296494T4 (da)	2022-07-18	Modermælkserstatning med fedtgradient
DK2265296T3 (da)	2012-10-01	Medicinske apparater med hydrofile belægninger
BRPI0912742A2 (pt)	2015-10-13	aquisição de topografia de objetos tendo geometrias arbitrárias
FR2930124B1 (fr)	2012-01-27	Meuble demontable
IT1395596B1 (it)	2012-10-16	Procedimento per la preparazione di sitagliptin
BR112013012547A2 (pt)	2016-08-09	antifúngicos 5,6-di-hidro-4h-pirrolo][1,4]benzodiazepinas e 6h-pirrolo [1,2-a] [1,4]benzodiazepinas substituídos por derivados de fenila
ITMI20080888A1 (it)	2009-11-16	Procedimento per la preparazione di zileuton
IT1391776B1 (it)	2012-01-27	Procedimento per la preparazione di dexlansoprazolo
FR2934997B1 (fr)	2010-09-24	Derives cyclopropyl-et cyclobutyl-dioxazaborocanes ou dioxazaborecanes
NO2019009I1 (no)	2019-02-20	abemaciklib eller farmasøytisk akseptable salter derav
IT1391811B1 (it)	2012-01-27	Procedimento per la fabbricazione di manufatti ceramici sostanzialmente piastriformi
UA20021S (uk)	2010-02-25	Набір м`яких меблів «фьюджи»
UA21094S (uk)	2010-11-25	Комплект м`яких меблів «люкс»
TH0901000513A (th)	2016-06-03	อนุพันธ์สไปโรไซคลิค แอมีดสำหรับการรักษาโรคปอด
IT1391758B1 (it)	2012-01-27	Procedimento per la preparazione di dexlansoprazolo amorfo